Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding : A qualitative systematic review
© American Society of Health-System Pharmacists 2024. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
DISCLAIMER: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
PURPOSE: The purpose of this review is to evaluate current literature on the treatment of factor Xa inhibitor-associated bleeds with 4-factor prothrombin complex concentrate (4F-PCC), with a focus on the effect of low versus high dosing of 4F-PCC on hemostatic efficacy and safety outcomes.
SUMMARY: A search of PubMed and EBSCOhost was performed to identify studies evaluating patients with a factor Xa inhibitor-bleed treated with 4F-PCC at either low or high doses. Studies of patients receiving alternative reversal agents such as fresh frozen plasma and andexanet alfa or where no comparator group was evaluated were excluded from the analysis. To assess the effect of these 4F-PCC dosing strategies, the primary outcome of interest was hemostatic efficacy. Four studies meeting inclusion criteria were included in this review. In each of the included studies, similar rates of hemostatic efficacy, hospital mortality, and venous thromboembolism were observed in the low- and high-dose cohorts.
CONCLUSION: These results suggest low- and high-dose 4F-PPC may confer similar clinical effectiveness and safety; however, these findings should be evaluated and confirmed with future prospective studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - (2024) vom: 02. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Phillips, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulation reversal |
|---|
| Anmerkungen: |
Date Revised 02.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/ajhp/zxae009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369200039 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369200039 | ||
| 003 | DE-627 | ||
| 005 | 20240302233025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajhp/zxae009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM369200039 | ||
| 035 | |a (NLM)38430127 | ||
| 035 | |a (PII)zxae009 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Phillips, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding |b A qualitative systematic review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © American Society of Health-System Pharmacists 2024. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a DISCLAIMER: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time | ||
| 520 | |a PURPOSE: The purpose of this review is to evaluate current literature on the treatment of factor Xa inhibitor-associated bleeds with 4-factor prothrombin complex concentrate (4F-PCC), with a focus on the effect of low versus high dosing of 4F-PCC on hemostatic efficacy and safety outcomes | ||
| 520 | |a SUMMARY: A search of PubMed and EBSCOhost was performed to identify studies evaluating patients with a factor Xa inhibitor-bleed treated with 4F-PCC at either low or high doses. Studies of patients receiving alternative reversal agents such as fresh frozen plasma and andexanet alfa or where no comparator group was evaluated were excluded from the analysis. To assess the effect of these 4F-PCC dosing strategies, the primary outcome of interest was hemostatic efficacy. Four studies meeting inclusion criteria were included in this review. In each of the included studies, similar rates of hemostatic efficacy, hospital mortality, and venous thromboembolism were observed in the low- and high-dose cohorts | ||
| 520 | |a CONCLUSION: These results suggest low- and high-dose 4F-PPC may confer similar clinical effectiveness and safety; however, these findings should be evaluated and confirmed with future prospective studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anticoagulation reversal | |
| 650 | 4 | |a bleeding | |
| 650 | 4 | |a factor Xa inhibitors | |
| 650 | 4 | |a hemostasis | |
| 650 | 4 | |a prothrombin complex concentrate | |
| 700 | 1 | |a Bradley, Colby |e verfasserin |4 aut | |
| 700 | 1 | |a Cash, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Sangiovanni, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Wingerson, Charles |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists |d 1995 |g (2024) vom: 02. März |w (DE-627)NLM075145952 |x 1535-2900 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajhp/zxae009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 03 | ||